Medical Bulletin 20/September/2022
Here are the top medical news for the day:High intake of whole grains, fiber, fish and omega-3 fatty acids linked to lower risk of death in adults with type 2 diabetesEating a diet high in whole grains, fibre, fish and n-3 polyunsaturated fatty acids (PUFAs) may reduce the risk of dying from all causes in adults with type 2 diabetes (T2D), according to a systematic review and...
Login or Register to read the full article
Here are the top medical news for the day:
High intake of whole grains, fiber, fish and omega-3 fatty acids linked to lower risk of death in adults with type 2 diabetes
Eating a diet high in whole grains, fibre, fish and n-3 polyunsaturated fatty acids (PUFAs) may reduce the risk of dying from all causes in adults with type 2 diabetes (T2D), according to a systematic review and meta-analysis synthesising all the available evidence, presented at this year's European Association for the Study of Diabetes (EASD) Annual Meeting.
To find out more, German researchers did a systematic review of 107 prospective observational studies investigating any dietary factors and the risk of death from all causes in adults with T2D, up to June 2022.
Reference:
Dr Olaf Spörkel et al,MEETING The European Association for the Study of Diabetes Annual Meeting
WHO strongly advises against antibody treatments for COVID-19 patients
The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with covid-19, says a WHO Guideline Development Group of international experts in The BMJ today.
These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.
Today's strong recommendation replaces previous conditional recommendations for their use and is based on emerging evidence from laboratory studies that these drugs are not likely to work against currently circulating variants, such as omicron.
Reference:
Rapid Recommendations: A living WHO guideline on drugs for covid-19, The BMJ, DOI: 10.1136/bmj.m3379
COVID-19: One in three infected but unvaccinated persons no longer have detectable antibodies one year after the infection
A prospective seroprevalence study in the Catalan population underlines the need to get vaccinated despite having been infected, and confirms that hybrid immunity (vaccination plus infection) is more robust and long-lasting.
Both infection and vaccination against SARS-CoV-2 contribute to building a population's immunity to the virus - an important factor for deciding when and to whom booster shots should be offered. Although immunity against a pathogen is more than antibodies, the easiest strategy for assessing population immunity is to perform seroepidemiological studies.
Reference:
Marianna Karachaliou et al,SARS-CoV-2 infection, vaccination and antibody response trajectories in adults: a cohort study in Catalonia.10.1186/s12916-022-02547-2
Gay men are two times more likely to have inflammatory bowel disease, according to new research
Gay men are more than twice as likely to develop inflammatory bowel disease (IBD) than heterosexual men when both populations engage in high-risk sexual activity, according to new research from the Digestive Health Research Institute at Case Western Reserve University and University Hospitals Cleveland Medical Center (UH).
The team evaluated self-reported data from patients treated at 58 healthcare organizations in the U.S. between 2002 and 2022.
Reference:
Emad Mansoor et al,Epidemiology of inflammatory bowel disease in men with high-risk homosexual activity,Gut
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd